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Abstract The polypeptideN-acetylgalactosaminyltransferase
(GalNAc-Ts) family of enzymes regulates the critical initial
steps of mucin-type O-glycosylation. Among GalNAc-Ts that
may significantly influence cancer biology, thus affecting cell
differentiation, adhesion, invasion, and/or metastasis,
GalNAc-T3 exhibits a high expression in several human can-
cers, closely associated with tumor progression and a poor
prognosis. However, the expression pattern of GalNAc-T3
in oral squamous cell carcinoma (OSCC) remains obscure.
Since postoperative recurrence of even early stage OSCC
(ESOSCC) occurs at an early phase, significantly affecting
their clinical course and worse outcome, the identification of
clinically significant accurate biomarkers is needed. There-
fore, we investigated the correlation between the immunohis-
tochemical GalNAc-T3 expression and various clinicopatho-
logical characteristics and recurrence using 110 paraffin-
embedded tumor samples obtained from patients with surgi-
cally resected ESOSCC (T1–2N0). Recurrence was
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recognized in 37 of 110 (33.6 %) patients. The GalNAc-T3
expression was considered to be strongly positive when 20 %
or more of the cancer cells showed positive cytoplasmic stain-
ing. Consequently, a strong expression of GalNAc-T3 was
observed in 40 patients (36.4 %), showing a close relationship
to poor differentiation, the presence of lymphatic and vascular
invasion, and recurrence. Univariate and multivariate analyses
further demonstrated that the patients with a strong GalNAc-
T3+ status had markedly lower disease-free survival (DFS)
rates, especially within the first 2 years postoperatively. There-
fore, GalNAc-T3 might play a role in the pathogenesis of
ESOSCC recurrence, and its immunohistochemical detection
potentially predicts a shorter DFS and may be a useful param-
eter for providing clinical management against ESOSCC in
the early postoperative phase.
Keywords Oral squamous cell carcinoma (OSCC) .
PolypeptideN-acetylgalactosaminyltransferase 3
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Introduction
Oral cancer is the most common head and neck cancer, which
is the sixthmost commonmalignancyworldwide, including in
Japan. Currently, approximately 264,000 new cases are diag-
nosed each year, with oral squamous cell carcinoma (OSCC)
comprising more than 90 % histological types of these cases.
Of these cases, more than 128,000 patients die of the disease
annually, and the mortality rate of OSCC is 3.7 per 100,000 in
Japan alone [1–3]. Among various clinicopathological char-
acteristics, local recurrence and/or regional lymph node me-
tastasis in cases of postoperative OSCC in particular have
been proposed to be prognostic indicators [4–6]. Even early
stage OSCC (ESOSCC) lesions treated with surgery alone,
which more than 80 % can be cured by therapy, may exhibit
postoperative relapse within the first 2 to 3 years [6–8]. There-
fore, it is critical to predict which ESOSCC patients (T1–2N0)
are prone to recurrence/metastasis and mortality after surgery
using practically accurate biomarkers. The clinical picture of
OSCC is also significantly determined by the complex inter-
play among additional cellular alterations, e.g., epigenetic
modulation of the gene expression, at least in part [1, 4].
It is well known that the malignant transformation and
cancer progression have a close relationship with alter-
ations in cell surface carbohydrate antigens (CAs), as well
as frequent aberrant glycosylation [9]. Glycosylation, a
major type of post-translational modification of most se-
cretory and cellular proteins, is capable of altering their
physicochemical properties and biological activities, lead-
ing to change the functions of glycoproteins and trans-
form cellular phenotypes, especially in cancer.
O-glycosylation reportedly encompasses diverse classes of
glycoproteins and, particularly, mucin-type O-linked glycans
constitute up to 80 % of the total amount of CAs in mammals
[9–11]. Mucin-type O-glycosylation is initiated by uridine di-
phosphate (UDP) N-acetyl-α-D-galactosamine polypeptide
(GalNAc) N-acetylgalactosaminyltransferases (GalNAc-Ts).
GalNAc-Ts can catalyze the transfer of GalNAc from the sug-
ar donor UDP-GalNAc to serine and threonine residues on
protein synthesizing CAs in the Golgi apparatus and are the
largest glycosyltransferase enzyme families covering a single
known glycosidic linkage [12–14]. Abnormal O-linked gly-
cans expressed in many epithelial cancers are markedly asso-
ciated with the presentation of incompletely elongated and
shortened glycan structures, which may affect cell differenti-
ation, adhesion, invasion, and/or metastasis [10, 11]. The
GalNAc-Ts, classified as 27 family members and, to date,
consisting 24 members in human, show a tissue-specific ex-
pression and have different kinetic properties and acceptor
substrate specificities [14].Many studies, including ours, have
indicated that GalNAc-T3 should be significantly useful for
evaluating various types of carcinoma, including digestive
tract adenocarcinoma, lung adenocarcinoma, renal cell carci-
noma, prostatic adenocarcinoma, and ovarian adenocarcino-
ma [11, 15–24]. In contrast, there are no studies of possible
associations between the GalNAc-T3 expression in OSCC,
especially ESOSCC, and associated clinicopathological fea-
tures, such as patterns of tumor invasiveness, vessel perme-
ation, or the patient’s prognosis.
In the present study, we show for the first time that, in
patients with postoperative ESOSCC, a cytoplasmic strong
GalNAc-T3 expression is significantly correlated with a short-
ened disease-free survival (DFS) and that this molecule might




All intended procedures in the present study, including the use
of specimens obtained from human subjects, were approved
by the Ethics Committee of the University of Occupational
and Environmental Health (UOEH) in Kitakyushu, Japan
(permission number H27-004), as well as written consent of
the patient’s next of kin according to the guidelines of the
Japanese Society of Pathology. Pathological reports were
reviewed to identify patients who had undergone surgical re-
section without neck lymph node dissection for ESOSCC be-
tween 1994 and 2015 at the hospital of UOEH.
There were no patients with perioperative death, defined as
death during the initial hospitalization or within 30 days of
surgery. A total of 110 surgically resected ESOSCC (T1–2N0)
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patients with available follow-up data comprised the cohort of
this retrospective study, as shown in Table 1, after further
excluding those with the following characteristics: (a) other
prior or concomitant malignant tumors; (b) coexisting medical
problems of sufficient disease severity to shorten life expec-
tancy; (c) involvement of the resection margin; and (d) the use
of neoadjuvant chemotherapy or radiotherapy prior to surgery.
The surgical margins were considered to be involved when the
presence of invasive carcinoma and/or carcinoma in situ at the
margin of the mucosa was identified, or the distance to the
non-carcinomatous mucosa margin was less than 5 mm.
Clinical information was thoroughly gathered from the pa-
tients’ records. The duration of survival (DFS and OS) was
defined as the interval from the date of surgery to recurrence
and death or the most recent clinic visit, respectively. In this
study, Brecurrence^ (37 cases; 33.6 %) included Blocal recur-
rence,^ Bsubsequent regional lymph node metastasis,^ and
Blocoregional recurrence.^ BLocal recurrence^ (13 cases;
11.8 %) was defined as lesions arising in the oral cavity rela-
tive to the primary tumor beyond 6 weeks within the first
5 years after the first definitive treatment. Meanwhile, recur-
rence arising in the neck was defined as Bsubsequent regional
lymph node metastasis^ (29 cases; 26.4 %), and recurrence
arising at both the primary site and in the neck was defined as
Blocoregional recurrence^ (5 cases; 4.5 %), as shown in Ta-
ble 2. Patients with recurrence considered to be potentially
curable and operable (35 cases; 31.8 %) underwent salvage
surgery with radiotherapy (eight cases) or radiotherapy and
adjuvant chemotherapy (six cases), as follows: carboplatin
(two cases), fluorouracil plus carboplatin (two cases),
cetuximab (one case), and docetaxel (one case), respectively.
Another two inoperable (1.8%) patients received radiotherapy
and chemotherapy, as follows: fluorouracil plus carboplatin
(one case) and cetuximab (one case). All patients were follow-
ed up every 2 weeks and 1 month within the first and second
postoperative year, respectively, and at approximately 2- to 6-
month intervals thereafter using visual inspection of the oral
cavity and/or neck CT scans. Chest X-ray was performed ev-
ery 6 months for 5 years after surgery. Additional examina-
tions, including brain, chest and abdominal CT, MRI, and
bone scintigraphy, were performed rarely in cases involving
signs or symptoms of recurrence.
Tissue specimens
Formalin-fixed, paraffin-embedded tissue blocks were provid-
ed by our Department of Pathology. Three pathologists exam-
ined all resected specimens to confirm the histopathological
features. The stage grouping of the tumors was classified ac-
cording to the TNM classification of malignant tumors, sev-
enth edition [25]. The mode of invasion was examined at the
host/tumor interface as previously defined by Yamamoto et al.
[26]. Each patient was assigned an Eastern Cooperative



















































ECOG PS Eastern Cooperative Oncology Group performance status, v
vascular invasion, ly lymphatic vessel invasion, ne perineural
involvement
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Oncology Group performance status (ECOG PS) score at the
time of diagnosis [27]. Non-carcinomatous tissue and recur-
rent OSCC tissue were obtained from non-tumor portions of
the surgically resected specimens and metastatic regional
lymph nodes or locally recurrent oral mucosa corresponding
to each primary site, respectively. These tissues were stained
with hematoxylin and eosin (H&E), Elastica van Gieson
(EVG), or immunohistochemistry preparations of sequential
sections. EVG, immunohistochemical Podoplanin (D2-40;
Nichirei Bioscience Co., Tokyo, Japan; diluted 1:1), and S-
100 protein (Dako, Glostrup, Denmark; diluted 1:900) stain-
ing very clearly revealed vascular invasion (v), lymphatic ves-
sel invasion (ly), and perineural involvement (ne), respective-
ly, as previously described [28].
Preparation of antibodies against GalNAc-T3 and other
GalNAc-Ts
A polyclonal antibody was raised against GalNAc-T3 using
multiple immunizations of New Zealand white rabbits with a
synthetic peptide, based on previously published work (se-
quence: GYYTAAELKPVLDRPPQDS) [29]. An anti-
GalNAc-T6 polyclonal antibody was generated in the same
way, as described in a previously published paper (synthetic
peptide sequence: GFYTPAELKPFWERPPQDP) [21]. The
specificity of our original antibody was confirmed onWestern
blotting (Fig. 1). Furthermore, we performed immunohisto-
chemistry with peptide competition against GalNAc-T3 [16,
29] and GalNAc-T6 [21], respectively. For immunohisto-
chemistry of GalNAc-T3 (diluted 1:1,000), we used well-
differentiated tubular colorectal adenocarcinoma cells as pos-
itive controls [11]. To analyze the staining or expression pro-
files of other GalNAc-Ts, anti-GalNAc-T1, anti-GalNAc-T2,
and anti-GalNAc-T4 goat monoclonal antibodies (1:100;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) and the
above anti-GalNAc-T6 (diluted 1:1,000) were applied,
respectively.
Cell culture
HSC-2 (humanOSCC cell line) was described previously [30]
and maintained in Eagle’s minimal essential medium contain-
ing 10% fetal bovine serum. COS-1 (monkey kidney cell line)
was described previously [31] and maintained in Dulbecco’s
modified Eagle’s medium containing 10 % fetal bovine se-
rum. Cell lines were maintained at 37 °C in an atmosphere
of 95 % air and 5 % CO2.
GalNAc-T3 siRNA knockdown and overexpression
Twenty-five base-pair double-stranded RNA oligonucleotides




3′ and 5′-CCCACCACCAGUGUCAUAAUAGUUU-3′ for
GalNAc-T3#86. siRNA transfection was performed as previ-
ously described [11]. A total of 5 μL of RNAiMAX (Life
technologies) was diluted in 250 μL of Opti-MEM medium
(Invitrogen, Carlsbad, CA, USA) and incubated for 5 min at
room temperature (RT). Next, 250 pmoL of siRNA for
GalNAc-T3 and RNAiMAX as control siRNA diluted in
250 μL of Opti-MEM were gently added and incubated for
20 min at RT. Oligomer-RNAiMAX complexes and aliquots
of 2×105 HSC-2 in 500 μL of culture medium were combined
and incubated. To obtain pcDNA3-GalNAc-T3 expression plas-
mid, human full length GalNAc-T3 cDNAwas amplified with
the primer pairs 5′-CCATGGCTCACCTAAAGCGACTAG-3′
and 5′-TTAATCATTTTGGCTAAGTATCC-3′ and ligated in
multi-cloning site of pcDNA3 mammalian expression plasmid
(Invitrogen). Underlines indicate start or stop codons. Transfec-
tion of expression plasmid was described previously [32].
Western blotting
Transfected cells with siRNAs or expression plasmid were
harvested after 48 h, and a Western blotting analysis was per-
formed as previously described [11]. In total, 30 μg of protein
from whole cell lysates was separated via sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred to
polyvinylidene difluoride microporous membranes
(Millipore, MA, USA). The blotted membranes were treated
with 5 % (w/v) skim milk and incubated for 1 h at RTwith the
primary antibody (diluted 1:1,000). Next, the membrane was
incubated for 45 min at RTwith a peroxidase-conjugated sec-
ondary antibody and visualized using an ECL kit (GE
Table 2 Outcome of the
recurrence status in the patients
on the end of this study
Total (n=110) % of all % of recurrent group
No recurrence 73 66.4
Recurrencea 37 33.6
Local recurrence 13 11.8 35.1
Subsequent regional lymph node metastasis 29 26.4 78.4
a Locoregional recurrence: n=5
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Healthcare Bio-Science, Buckinghamshire, UK). Detection
was performed with an LAS-4000 mini (Fujifilm, Tokyo,
Japan).
Immunofluorescence of HSC-2
HSC-2 was cultured on coverslips, then incubated with anti-
GalNAc-T3 (diluted 1:1,000) and anti-GalNAc-T6 (diluted
1:1,000) rabbit polyclonal antibodies or anti-GalNAc-T1, an-
ti-GalNAc-T2, and anti-GalNAc-T4 goat monoclonal anti-
bodies (diluted 1:100; Santa Cruz Biotechnology) for 1 h at
RT, respectively. These cells were then further incubated with
Hoechst 33258 (blue-stained) (0.5 mg/mL; Dojindo, Kuma-
moto, Japan) and visualized with goat anti-rabbit or donkey
anti-goat IgG antibodies conjugated with Alexa Fluor dyes
(green-stained), respectively [11]. After being washed with
PBS, the specimens were observed under a Nikon ECLIPSE
E600 inverted fluorescence microscope (Nikon, Tokyo,
Japan).
Immunohistochemistry of the tissue samples
Immunohistochemical staining was performed according to
the antibody-linked dextran polymer method for antibody-
bridge labeling, with hematoxylin counterstaining (EnVision;
DAKO). Deparaffinized and rehydrated 4-μm sections were
incubated in 10 % H2O2 for 5 min to block the endogenous
peroxidase activity. The sections were subsequently rinsed
and incubated with rabbit polyclonal anti-GalNAc-T3 (diluted
1:3,000) antibodies for 30 min, respectively. The second
antibody-peroxidase-linked polymers were then applied, and
the sections were incubated with a solution consisting of
20 mg of 3.3′-diaminobenzidine tetrahydrochloride, 65 mg
of sodium azide, and 20 mL of 30 % H2O2 in 100 mL of
Tris–HCl (50 mM, pH 7.6). After counterstaining with
Meyer’s hematoxylin, the sections were observed under a
light microscope. Each section was first scanned at low power
for all fields (original magnification: ×40) using tumor and
non-tumor tissues, respectively, in order to determine the het-
erogeneity of the distribution. The number of positive cells
showing cytoplasmic staining was recorded in the site of in-
vasion. Necrotic tissues, stromal cells, and lymphoid cells
were not included in the recordings.
The degree of immunoreactivity for GalNAc-T3 was
assessed in each case semi-quantitatively by evaluating the
proportion of positive cells relative to the total number of
ESOSCC cells. Samples with positive areas comprising equal
to or more than 20 % of the neoplasms were considered to be
strongly positively stained. We selected and validated immu-
nohistochemical cutoff scores for GalNAc-T3 positivity,
based on the findings of a receiver operating characteristic
(ROC) curve analysis [33]. Finally, all patients were divided
into two groups, as follows: those with strongly positive find-
ings, equal to or more than 20 %, and those with weakly
positive (including negative) findings, less than 20 %.
All histological and immunohistochemical slides were
evaluated by two independent observers using a blind protocol
design (the observers were blinded to the clinicopathological
data). The degree of agreement between the observers was
excellent (an agreement rate of more than 95 %) for all anti-
bodies investigated, as measured according to the interclass
correlation coefficient. For the very few (much less than 1 %)
instances of disagreement, a consensus score was calculated
by a third board-certified pathologist in our department [11,
28, 34, 35].
Statistical analysis
The significance of correlations was determined based on χ2
test or Fisher’s exact test, where appropriate, in order to assess
the relationships between the immunohistochemical expres-
sion levels and the clinicopathological variables [11, 30]. Sur-
vival curves were plotted according to the Kaplan–Meier










Fig. 1 The specificity of our original polyclonal antibody for GalNAc-
T3 was confirmed using Western blotting. a AWestern blotting analysis
confirmed the specificity of the GalNAc-T3 antibody. HSC-2 cells were
transfected with siRNA control and GalNAc-T3 siRNA knockdown (no.
85 and no. 86), and 30-μg protein from whole cell lysates was applied.β-
actin was used as an internal control. b COS-1 cells were transfected with
GalNAc-T3 expression plasmid, and 30 μg protein from whole cell ly-
sates was applied
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and 95 % confidence intervals (95 % CIs) were estimated
using univariate or multivariate Cox proportional hazard
models. All statistical tests were two-tailed, with a P value
of <0.05 considered to be statistically significant. All statisti-
cal analyses were performed with the EZR software program
(Saitama Medical Center, Jichi Medical University, Japan), a
graphical user interface for R (The R Foundation for Statistical
Computing, version 2.13.0) [35, 36]. More precisely, this pro-
gram is a modified version of R commander (version 1.6-3)
designed to add statistical functions frequently used in
biostatistics.
Results
Confirmation of the specificity of the GalNAc-T3
antibody
Specificity, a GalNAc-T3 polyclonal antibody, was tested
using immunohistochemistry and Western blotting, as previ-
ously described [11]. In this study, Western blotting revealed
that GalNAc-T3 proteins were expressed in the HSC-2 cells
(Fig. 1a), whereas GalNAc-T6 staining was weak (data not
shown). We thus performed siRNA transfection of GalNAc-
T3 into the wild-type HSC-2 cells, which demonstrated that
the expression of about 90 kDa protein was significantly de-
creased in the HSC-2 cells of GalNAc-T3 siRNA (Fig. 1a).
Further, about 90 kDa protein was detected in cells transfected
with GalNAc-T3 expression plasmid (Fig. 1b). TheseWestern
blotting results indicate that the GalNAc-T3 antibody was
specific for its protein. Immunofluorescence staining of the
OSCC cell line (HSC-2) showed a specific expression of
GalNAc-T3 in a cytoplasmic, perinuclear fashion but not in
nuclei (Supplementary Fig. 1). In contrast, other GalNAc-Ts (-
T1, -T2, -T4, and -T6) were not or very weakly expressed in
the HSC-2 cells (Supplementary Fig. 1).
Patient characteristics
The cohort included 110 patients (61 males, 49 females)
with clinicopathological variables representative of
ESOSCC (Table 1). The average age at surgery was
64.3 years. A total of 100 (90.9 %) and 10 (9.1 %)
patients had an ECOG status equal to or less than 1
and more than 2, respectively. The median tumor size
was 2.0 cm (range=0.2–3.8 cm). At diagnosis, no pa-
tients had either lymph node or distant metastasis. The
tumor grade included 68 well-differentiated lesions
(61.8 %), 30 moderately differentiated lesions (27.3 %),
and 12 poorly differentiated lesions (10.9 %) of squa-
mous cell carcinoma. Based on the (TNM) classification
of malignant tumors, seventh edition, the ESOSCC pa-
tients had stage I (56/110; 50.9 %) and II (54/110;
49.1 %) disease, respectively. Postoperative follow-up
was available for all 110 patients (average=67.2 months;
range=1–236 months). The median OS was 56.6 months,
with 2- and 5-year survival rates of 92.9 and 90.9 %,
respectively. Moreover, the median DFS was 26.5 months
with 2- and 5-year survival rates of 67.5 and 61.9 %,
respectively. Supplementary Table 1 displays each pa-
tient’s information in detail.
GalNAc-T3 expression in the non-carcinomatous oral
mucosal tissues, ESOSCC specimens, and recurrent
OSCC specimens of lymph nodes or mucosa
On immunohistochemistry, GalNAc-T3 showed cytoplasmic
expression patterns in the typically strongly positive cancer
cases (Fig. 2), especially at the invasive front. Representative
images of the immunohistochemical findings of the human
ESOSCC samples associated with a shortened DFS (i.e., early
recurrence) or no recurrence are shown in Supplementary Ta-
ble 1 (case nos. 25 or 71), respectively (Fig. 2). In contrast, a
cytoplasmic GalNAc-T3 expression was very weakly, but on
occasion, diversely, detectable of adjacent non-carcinomatous
squamous epithelium (normal to dysplasia) in the paraffin-
embedded tissues (Fig. 2). GalNAc-T3 was weakly and
strongly positively expressed in 70 (63.6 %) and 40
(36.4 %) of the 110 ESOSCC specimens, respectively
(Table 3 and Fig. 2). In particular, GalNAc-T3 was strongly
or weakly expressed in 19 (54.3 %) and 16 (45.7 %) of 35
recurrent ESOSCC specimens of lymph nodes or correspond-
ing oral mucosa, respectively. Moreover, the GalNAc-T3
staining patterns were borderline significantly consistent with
those of the corresponding primary OSCC specimens (P=
0.05), especially the recurrent pattern of subsequent regional
lymph node metastasis (Table 2 and Supplementary Table 2),
as described later in detail. Representative H&E and immuno-
histochemical GalNAc-T3 sections are shown with a strong
expression of OSCC in both the primary oral mucosa and
metastatic regional lymph nodes (case no. 21 in
Supplementary Table 1) (Fig. 3).
Associations between the GalNAc-T3 expression
and the clinicopathological variables and pattern
of recurrence
In order to identify associations between the GalNAc-T3
expression (weakly vs. strongly positive) and the clinico-
pathological characteristics of the study cohort, the vari-
ables were categorized as shown in Table 3. Consequent-
ly, a GalNAc-T3 strongly positive expression was found
to be significantly or borderline (in)significantly associ-
ated with poor differentiation (P=0.03), the presence of
v (P=0.04) and ly (P=0.03) and recurrence (P=0.01) or
an older age (P=0.05) in all tumors (Table 3 and
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Supplementary Fig. 2), respectively. In contrast, there
were no significant differences between the patients with
weakly and strongly positive GalNAc-T3 ESOSCC ex-
pression patterns in terms of gender, ECOG PS,
smoking, alcohol use, tumor T stage, location, mode of
invasion, and presence of ne (P>0.05) (Table 3). In
particular, a strong GalNAc-T3+ expression was evident in
v(+) and ly(+) (v; case no. 25, ly; case no. 2 in
Supplementary Table 1) representative OSCC components,
as shown on EVG and D2-40 staining, respectively (Supple-
mentary Fig. 2).
Additionally, in order to elucidate the correlations between
the GalNAc-T3 expression (weakly vs. strongly positive) and
the pattern of recurrence in the study cohort, the variables
were also categorized as presented in Supplementary Table 2.
A strongly positive GalNAc-T3 expression was revealed to be
borderline (in)significantly associated with Bsubsequent re-
gional lymph node metastasis^ (P=0.05), whereas there were
no significant differences in the patterns of Blocal recurrence^
and Blocoregional recurrence^ (P>0.05) (Supplementary
Table 2).
According to a Kaplan–Meier analysis, the patients with a
strong GalNAc-T3+ expression had a significantly shorter
postoperative median DFS (11.8 months) than those with a
weakGalNAc-T3+ expression (32.7 months), especially with-
in the first 2 rather than 5 years postoperatively (P<0.001
(2 years) and P<0.01 (5 years), respectively, Fig. 4a). How-
ever, there were no significant differences in postoperative OS
between the two groups of ESOSCC patients with a weak
(median=62.5 months) and strong (median=53.7 months)
GalNAc-T3+ status (P=0.302 (2 years) and P=0.915
(5 years), Fig. 4b).
A strong GalNAc-T3+ expression represents a significant
independent DFS indicator for ESOSCC by a Cox
proportional hazards model
A univariate analysis showed tumor differentiation (poorly),
mode of invasion of 4C and 4D, the presence of v and ly, and a
strong GalNAc-T3+ expression to be significant predictors of
a worse survival (P=0.03, 0.001, 0.01 and <0.001 and
<0.001, respectively). Furthermore, a multivariate analysis
demonstrated that, after correcting for confounding variables,
a strong GalNAc-T3+ expression only remained an indepen-
dent poor indicator for DFS (P=0.03), whereas a more aggres-
sive mode of invasion and the presence of ly were borderline
(P=0.05 and 0.05, respectively) (Table 4).
Discussion
The current study showed for the first time that an
immunohistochemically cytoplasmic strong GalNAc-T3-
positive expression is a powerful and independent negative
indicator of DFS and potential worse outcome in patients with
postoperative ESOSCC, especially within the first 2 years af-
ter surgery. It is well known that recurrence in ESOSCC pa-
tients after curative surgery remains a significant problem and
can significantly affect their clinical postoperative course and
survival [6]. The biological aggressiveness of ESOSCC is
reflected by the capability of carcinoma to recur, even in small
OSCC lesions that are considered to have a relatively good
prognosis [in
Collectively, our present data are in agreement with the








Fig. 2 The cytoplasmic GalNAc-T3 expression patterns showed specif-
ically positive staining on immunohistochemistry, potentially associated
with early recurrence in the ESOSCC patients. Representative images of
immunohistochemically strong/weak positivity for GalNAc-T3 in the hu-
man ESOSCC samples are shown, demonstrating a cytoplasmic staining
pattern in the strong GalNAc-T3-positive cases with postoperative recur-
rence (case no. 25), compared to the scant cytoplasmic staining pattern in
the weak GalNAc-T3-positive cases without any recurrence (case no. 71)
(Original magnification: ×100; inset, ×400). In contrast, a cytoplasmic
GalNAc-T3 expression was very weakly detectable of adjacent non-
carcinomatous squamous epithelium (normal to dysplasia). Each inset
provides a representative image of ESOSCC carcinomatous and non-
carcinomatous nuclei and cytoplasm on high-power view. H&E hema-
toxylin and eosin. Bars=200 μm (×100) and 20 μm (×400)
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[11, 15–24]. For example, kidney epithelial cancer has recent-
ly shown a significantly upregulated GalNAc-T3 expression
closely associated with more aggressive tumor characteristics
and worse prognosis [11]. The present cohort study




Variables Total GaINAc T3 expression
(%) Weak+ (n=70) Strong+ (n=40) P value
Age 0.05
>60 32 29.1 25 (78.1) 7 (219)
≦60 78 70.9 45 (57.7) 33 (42.3)
Sex 0.24
Male 61 55.5 42 (68.9) 19 (31.1)
Female 49 44.5 28 (57.1) 21 (42.9)
ECOG PS 0.74
0–1 100 90.9 63 (63.0) 37 (37.0)
2–4 10 9.1 7 (70.0) 3 (30.0)
Smoking 0.17
(−) 51 46.4 36 (70.6) 15 (29.4)
(+) 59 53.6 34 (57.6) 25 (42.4)
Alcohol 0.43
(−) 49 44.5 29 (59.2) 20 (40.8)
(+) 61 55.5 41 (67.2) 20 (32.8)
T stage 0.11
T1 59 53.6 42 (71.2) 17 (28.8)
T2 51 46.4 28 (54.9) 23 (45.1)
Tumor location 0.32
Tongue 65 59.1 39 (60.0) 26 (40.0)
Maxilla 7 6.4 5 (71.4) 2 (28.6)
Mandible 9 8.2 4 (44.4) 5 (55.6)
Buccal 10 9.1 6 (60.0) 4 (40.0)
Floor of mouth 18 16.4 15 (83.3) 3 (16.7)
Hard palate 1 0.9 1 (100) 0 (0.0)
Differentiation 0.03
Well, moderately 98 89.1 66 (67.3) 32 (32.7)
Poorly 12 10.9 4 (33.3) 8 (66.7)
Mode of invasion 0.40
1–3 95 86.4 62 (65) 33 (32.7)
4C, 4D 15 13.6 8 (53.3) 7 (46.7)
Vascular invasion 0.04
v(−) 101 91.8 62 (65) 33 (34.7)
v(+) 9 8.2 2 (22.2) 7 (77.8)
Lymphatic vessel invasion 0.03
ly(−) 92 83.6 63 (68.5) 29 (31.5)
ly(+) 18 16.4 7 (38.9) 11 (61.1)
Perineural involvement 0.55
ne(−) 107 97.3 67 (62.6) 40 (37.4)
ne(+) 3 2.7 3 (38.9) 0 (0.0)
Recurrence 0.01
(−) 73 66.4 53 (72.6) 20 (27.4)
(+) 37 33.6 17 (46) 20 (54.1)
ECOG PS Eastern Cooperative Oncology Group performance status, v vascular invasion, ly lymphatic vessel
invasion, ne perineural involvement
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demonstrated GalNAc-T3 to be a powerful and independent
negative indicator of DFS, i.e., a novel marker of recurrence,
in patients with postoperative ESOSCC. As to the OS, there
were no apparent correlations with a strong GalNAc-T3+ ex-
pression of ESOSCC in our study, with the limitations of
assessing an unlikely large cohort at a single institution. In
fact, all collected patients had surgically resected T1–2N0
ESOSCCs with a more favorable prognosis, showing a 5-
year survival rate of 90.9 % compared with that of up to
86 % reported in previous studies [6]. Further follow-up with
a larger cohort is therefore needed to confirm the intriguing
relationships between a strong GalNAc-T3+ expression and
poor outcome in postoperative ESOSCC patients.
Our findings indicate for the first time that a strong
GalNAc-T3+ expression in ESOSCC is significantly closely
correlated with poor differentiation and the presence of vessel
H&E
GalNAc-T3
Primary ESOSCC Recurrent ESOSCCFig. 3 GalNAc-T3 staining
patterns significantly




T3 sections are presented with
a strong expression of early
recurrent ESOSCC in both the
primary oral mucosa and
metastatic regional lymph node
(case no. 21). H&E hematoxylin
and eosin. Bars=200 μm (×100)
and 20 μm (×400)


























































Fig. 4 A strong GalNAc-T3-
positive expression was
associated with a significantly
shorter postoperative DFS, but
not OS, in the ESOSCC patients,
especially within the first 2 years
postoperatively. a Kaplan–Meier
curves for DFS in the patients
with ESOSCC within the first 2
(left) and 5 (right) years after
surgery according to the GalNAc-
T3 expression. b Kaplan–Meier
curves for OS in the patients with
ESOSCC within the first 2 (left)
and 5 (right) years after surgery
according to the GalNAc-T3 ex-
pression. DFS disease-free
survival, OS overall survival
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permeation (v(+) and ly(+)), most likely manifesting as sig-
nificant invasive/aggressive behaviors. These results also ac-
cord with those of our recent study of clear cell renal cell
carcinoma [11], that the GalNAc-T3+ expression significantly
ameliorates adhesive effects together with a significantly low
expression of β-catenin, seemingly leading to severe v(+).
Moreover, other groups have focused on modulation of the
cell adhesion function by GalNAc-T3 overexpression, which
is involved in invasion/metastasis of the ovarian adenocarci-
noma via abnormal glycosylation of O-glycoprotein mucin 1
Table 4 Univariate and multivariate analyses of survival (DFS) among the 110 patients with ESOSCC according to the clinicopathological variables
and the strong GalNAc-T3 expression
Variables No. of patients (%) Univariate Multivariate
Disease-free Disease HR 95 % CI P value HR 95 % CI P value
Age
≦60 22 (68.8) 10 (31.3) 100
>60 51 (65.4) 27 (34.6) 1.26 0.61–2.62 0.53
Sex
Female 31 (63.3) 18 (36.7) 1.00
Male 42 (68.9) 19 (31.1) 0.85 0.45–2.30 0.25
ECOG PS
0–1 64 (64.0) 36 (36.0) 1.00
2–4 9 (90.0) 1 (10.0) 0.31 0.04–2.30 0.25
Smoking
(−) 34 (66.7) 17 (33.3) 1.00
(+) 39 (66.1) 20 (33.9) 1.08 0.56–2.06 0.82
Alcohol
(−) 22 (68.8) 10 (31.3) 1.00
(+) 51 (65.4) 27 (34.6) 1.55 0.79–3.00 0.20
T stage
T1 42 (71.2) 17 (28.8) 1.00
T2 31 (60.8) 20 (39.2) 1.53 0.80–2.91 0.20
Tumor location
Maxilla, mandible, buccal 23 (65.7) 12 (34.3) 1.00
Tongue, floor of mouth 50 (66.7) 25 (33.3) 1.20 0.50–2.40 0.82
Differentiation
Well, moderately 68 (69.4) 30 (30.6) 1.00 1.00
Poorly 5 (41.7) 7 (58.3) 2.53 1.11–5.79 0.03 0.69 0.19–2.54 0.58
Mode of invasion
1, 2, 3 68 (71.6) 27 (28.4) 1.00 1.00
4C, D 5 (33.3) 10 (66.7) 3.29 1.59–6.82 0.001 3.23 1.02–10.6 0.05
Vascular invasion
v(−) 70 (69.3) 31 (30.7) 1.00 1.00
v(+) 3 (33.3) 6 (66.7) 3.54 1.47–8.52 0.01 2.25 0.87–5.78 0.09
Lymphatic vessel invasion
ly(−) 68 (73.9) 24 (26.1) 1.00 1.00
ly(+) 5(27.8) 13 (72.2) 3.96 1.98–7.91 <0.001 2.18 1.01–4.71 0.05
Perineural involvement
ne(−) 71 (66.4) 36 (33.6) 1.00
ne(+) 2 (66.7) 1 (33.3) 0.87 0.12–6.34 0.89
GalNAc-T3 expression
Weak+ 53 (75.7) 17 (24.3) 1.00 1.00
Strong+ 20 (50.0) 20 (50.0) 2.81 1.47–5.37 0.002 2.23 1.06–4.80 0.03
v vascular invasion, ly lymphatic vessel invasion, ne perineural involvement
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(MUC1), potentially accompanied by the downregulated ex-
pression of E-cadherin and β-catenin [24]. Taken together, we
can support our hypotheses that GalNAc-T3 accelerates
ESOSCC invasion/metastasis by affecting epithelial–mesen-
chymal transition (EMT) at least in part, as previously de-
scribed [11, 21]. Furthermore, our immunohistochemical
examination of ESOSCC tissues showed a strong subcel-
lular cytoplasmic staining pattern for GalNAc-T3 espe-
cially at the invasive fronts. Whereas, weakly but, on oc-
casion, diversely positive staining was identified in the
adjacent non-carcinomatous squamous epithelium (normal
to dysplasia). It is conceivable that GalNAc-T3 potentially
plays a critical role in acquired OSCC aggressiveness as
well as carcinogenesis through aberrant O-linked glyco-
sylation. Since GalNAc-Ts reportedly appear in external
secretions into body fluids [37, 38], GalNAc-T3 would be
a quantitative soluble marker. In this scenario, these find-
ings lead us to speculate that GalNAc-T3 might be not
only a predictive factor of occult metastasis or specific
tumor marker for OSCC but also an ideal therapeutic tar-
get against ESOSCC, together with minimum risk of side
effects. Nevertheless, further in-depth in vitro and in vivo
analyses, including real-time quantitative polymerase
chain reaction (qRT-PCR), are needed to elucidate these
issues.
In conclusion, the present cohort study demonstrated for
the first time that a strong GalNAc-T3+ expression is an in-
dependent, novel, and powerful marker of a worse DFS in
ESOSCC patients, especially within the first 2 years, even
after curative surgery. Patients with ESOSCC showing strong
GalNAc-T3+ expression should be followed up very careful-
ly. Therefore, physicians should assess the value of this critical
ESOSCC-specific biomarker, GalNAc-T3, as a useful param-
eter for clinical management, particularly in the early postop-
erative phase.
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